On the evening of April 20, Beike Biotech (688276) released its 2024 annual report showing that during the reporting period, the company's operating income was approximately 1.229 billion yuan, a year-on-year decrease of 32.64%; the corresponding attributable net profit was approximately 232 million yuan, a year-on-year decrease of 53.67%. It is planned to pay a cash dividend of 1.69 yuan (including tax) per 10 shares to all shareholders.

In this regard, the annual report pointed out that the main reason was the decrease in revenue and net profit due to the decrease in sales of herpes zoster vaccines during the reporting period; the net cash flow generated by operating activities was 406.5022 million yuan, 255.2070 million yuan in the same period last year, an increase of 59.28%, mainly due to the increase in sales proceeds; basic earnings per share, diluted earnings per share, basic earnings per share after deducting non-recurring gains and losses, and weighted average return on net assets decreased by 53.72%, 53.72%, 53.33%, and 5.21% respectively, mainly due to the year-on-year decrease in net profit this year.

During the reporting period, the company achieved main business income of 1229.0841 million yuan, a decrease of 32.64% over the same period last year, and main business costs of 179.1785 million yuan, an increase of 0.66% over the same period last year; the gross profit margin of the main business was 85.42%, a decrease of 4.82 percentage points over the same period last year.

At the same time, Beike Bio released its first quarter report for 2025, showing that during the reporting period, the company achieved operating income of approximately 162 million yuan, a year-on-year decrease of 39.96%; the corresponding attributable net profit was approximately 1.0643 million yuan, a year-on-year decrease of 98.24%.

Regarding the decline in revenue, the company said that it was mainly due to the year-on-year decline in sales revenue of herpes zoster vaccines during the reporting period. Regarding the sharp decline in net profit, Beike Bio said that it was mainly due to the decrease in sales of herpes zoster vaccines during the reporting period, which led to a decline in revenue, and the company's layout of new sales channels, increased promotion and publicity efforts, and increased sales expenses this quarter.

Beike Bio is a high-tech biopharmaceutical company specializing in the research and development, production and sales of human vaccines. The company currently has approved vaccine products such as varicella vaccine, nasal spray influenza vaccine, and herpes zoster vaccine.

Not long ago, Yu Bing, former deputy general manager of Beike Bio, resigned and later joined Kangtai Biological as vice president.

On February 14, Beike Bio announced that the board of directors recently received a written resignation report from Yu Bing, the company's non-independent director and deputy general manager, who applied to resign from the company's director and deputy general manager for personal reasons. After resigning from the above positions, Yu Bing no longer holds any position in the company. As of the date of resignation, Yu Bing directly held 1.0034 million shares of Beike Bio, accounting for approximately 0.24% of the company's total share capital.

Public information shows that 48-year-old Yu Bing joined Beike Bio in February 2019 and served as deputy general manager, and served as a director in December 2024. During his tenure as deputy general manager of Beike Bio, Yu Bing has been responsible for marketing-related work. In the eyes of the outside world, Yu Bing single-handedly promoted the commercialization of Beike Bio's varicella vaccine, nasal spray influenza vaccine, and shingles vaccine.

In the secondary market, as of the close of April 18, Beike Bio's share price was 21.83 yuan per share, with a total market value of 9.03 billion yuan. The stock price has fallen by nearly 40% since its listing.

https://finance.eastmoney.com/a/202504203382154649.html